ホーム > 松阪 諭/ Matsusaka, Satoshi

松阪 諭

ALUMNI 2025年5月現在、筑波大学が主たる所属機関ではありません

Matsusaka, Satoshi

医学医療系 , 教授
Faculty of Medicine , Professor
オープンアクセス版の論文は「つくばリポジトリ」で読むことができます。
  1. 1. Virtual-freezing fluorescence imaging flow cytometry with 5-aminolevulinic acid stimulation and antibody labeling for detecting all forms of circulating tumor cells Matsumura, Hiroki; Shen, Larina Tzu-Wei; Isozaki, Akihiro; Mikami, Hideharu (+15 著者) Matsusaka, Satoshi
      Lab on a chip 23: 1561 (2023) Semantic Scholar
  2. 2. Simultaneous Detection and HER2 Profiling of Circulating Breast Cancer Cells in Clinical Patients Using a Rare Cell Sorter Mori, Tomoko; Furukawa, Atsuko; Bilal, Turan; Ueda, Aya (+3 著者) Matsusaka, Satoshi
      Anticancer research 42: 4879 (2022) Semantic Scholar
  3. 3. Longitudinal investigation of a xenograft tumor zebrafish model using polarization-sensitive optical coherence tomography Lichtenegger, Antonia; Tamaoki, Junya; Licandro, Roxane; Mori, Tomoko (+8 著者) Yasuno, Yoshiaki
      Scientific reports 12: (2022) Semantic Scholar
  4. 4. Three dimensional tumor spheroid drug response evaluation using OCT based tissue viability evaluation method Abd El-Sadek; Ibrahim; Miyazawa, Arata; Mori, Tomoko (+4 著者) Yasuno, Yoshiaki
      Proceedings Volume 11948, Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XXVI (2022)
  5. 5. Deep convolutional neural network-based scatterer density and resolution estimators in optical coherence tomography Yasuno, Yoshiaki; Seesan, Thitiya; Abd El-Sadek, Ibrahim; Mukherjee, Pradipta (+6 著者) Makita, Shuichi
      Biomedical Optics Express 13: 168 (2022) Semantic Scholar
  6. 6. Multi-functional optical coherence microscopy for in-vitro and ex-vivo tissue investigation Yasuno, Yoshiaki; Abd El-Sadek; Ibrahim; Miyazawa, Arata (+11 著者) Matsusaka, Satoshi
      Proceedings Volume 11924, Optical Coherence Imaging Techniques and Imaging in Scattering Media IV (2021)
  7. 7. Volumetric multi-contrast dynamics imaging for ex vivo liver microvasculature activity visualization using Jones matrix optical coherence tomography. Mukherjee, P; Miyazawa, A; Shen, L. T. W; Fukuda, S (+8 著者) Yasuno, Y
      Proc. SPIE (2021)
  8. 8. Raman image-activated cell sorting Nitta, Nao; Iino, Takanori; Isozaki, Akihiro; Yamagishi, Mai (+28 著者) Ota, Tadataka
      Nature communications (2020)
  9. 9. Intelligent Image-Activated Cell Sorting. Nao Nitta; Takeaki Sugimura; Akihiro Isozaki; Hideharu Mikami (+46 著者) Keisuke Goda
      Cell 175: 266 (2018) Semantic Scholar
  10. 10. A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study. M, Suenaga; T, Akiyoshi; E, Shinozaki; Y, Fujimoto (+8 著者) T, Yamaguchi
      Anticancer Res 17: e471 (2018)
  11. 11. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Hanna DL; F, Loupakis; D, Yang; C, Cremolini (+13 著者) HJ, Lenz
      Clin Colorectal Cancer. 17: e471 - e488 (2018)
  12. 12. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06) Yutaka Kimura; Masashi Fujii; Toshiki Masuishi; Kazuhiro Nishikawa (+41 著者) on behalf of the JACCRO GC-06 Study Group
      Gastric Cancer 21: 421 (2018) Semantic Scholar
  13. 13. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Matsusaka, S; Wu, AH; Cao, S; Hanna, DL (+14 著者) Lenz, HJ
      Pharmacogenomics J. 18: 262 (2018)
  14. 14. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Martin D Berger; Sebastian Stintzing; Volker Heinemann; Shu Cao (+15 著者) Heinz-Josef Lenz
      Clinical cancer research : an official journal of the American Association for Cancer Research 24: 784 (2018) Semantic Scholar
  15. 15. A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: Results from FIRE-3 and JACCRO 05 and 06 trials A. Sebio; S. Stintzing; V. Heinemann; Y. Sunakawa (+13 著者) H. J. Lenz
      Pharmacogenomics Journal 18: 43 (2018) Semantic Scholar
  16. 16. Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer Y. Sunakawa; S. Cao; N. B. Volz; M. D. Berger (+14 著者) H-J Lenz
      PHARMACOGENOMICS JOURNAL 17: 528 (2017) Semantic Scholar
  17. 17. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy S. Matsusaka; S. Cao; D. L. Hanna; Y. Sunakawa (+16 著者) H-J Lenz
      PHARMACOGENOMICS JOURNAL 17: 543 (2017) Semantic Scholar
  18. 18. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Berger, MD; Stintzing S; Heinemann, V; Yang, D (+12 著者) Lenz, HJ
      Ann Oncol 28: 2780 (2017) Semantic Scholar
  19. 19. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Hosoya, K; Matsusaka, S; Kashiwada, T; Suzuki, K (+7 著者) Sueoka-Aragane, N
      Pathol Oncol Res. 23: 737 (2017) Semantic Scholar
  20. 20. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Okazaki, S; Stintzing, S; Sunakawa, Y; Cao, S (+14 著者) Lenz, HJ
      Int J Cancer 141: 1222 (2017) Semantic Scholar
1 2 3 4
  1. 1. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. Matsusaka, Satoshi
    Pharmacogenet Genomics. 2021年1月
  2. 2. A novel system to detect circulating tumor cells using two different size-selective microfilters. 松阪, 諭
    Anticancer Res. 2020年10月
  3. 3. Polymorphisms within immune regulatory pathways predict cetuximab efficacy and survival in metastatic colorectal cancer patients. 松阪, 諭
    2020年10月
  4. 4. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. 松阪, 諭
    PloS One. 2020年9月
  5. 5. Raman image-activated cell sorting. Matsusaka, Satoshi
    Nat Commun. 2020年7月
  6. 6. Sequentially addressable dielectrophoretic array for high-throughput sorting of large-volume bioliogical compartments. 松阪, 諭
    Sci Adv. 2020年5月
  7. 7. Virtual-freezing fluorescence imaging flow cytometry Matsusaka, Satoshi
    Nat Commun. 2020年3月
  8. 8. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Matsusaka, Satoshi
    Cancer Sci. 2020年2月
  9. 9. Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering. 松阪, 諭
    Proc Natl Acad Sci U S A. 2019年8月
  10. 10. A practical guide to intelligent image-activated cell sorting Matsusaka, Satoshi
    2019年8月
  11. 11. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). 松阪, 諭
    Radiother Oncol. 2019年5月
  12. 12. A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab. 松阪, 諭
    2018年2月
  13. 13. 医学のあゆみ 松阪,諭 (担当:分担執筆, 範囲:リキッドバイオプシー-がんにおける臨床応用と将来展望)
    医歯薬出版 2018年
  14. 14. 大腸癌FRONTIER 松阪, 諭; 畠精彦 (担当:分担執筆, 範囲:微量癌細胞検出の臨床的意義〜腫瘍内科医の立場から)
    2012年
  15. 15. Frontiers in Gastroenterology 松阪,諭 (担当:分担執筆, 範囲:大腸癌補助化学療法におけるオキサリプラチン使用の是非 肯定派)
    2012年
  16. 16. 最新医学 松阪,諭 (担当:分担執筆, 範囲:末梢循環血管内皮細胞(CEC)と末梢循環血管内皮前駆細胞(CEP))
    2011年
  17. 17. 細胞工学別冊 松阪, 諭; 三嶋雄二; 畠精彦 (担当:分担執筆, 範囲:CTCによるトランスレーショナルリサーチ)
    2010年
  18. 18. 医学のあゆみ 松阪,諭 (担当:分担執筆, 範囲:抗体医薬に対するバイオマーカー-末梢循環癌細胞(CTC), 末梢循環血管内皮細胞(CEC), 末梢循環血管内皮前駆細胞(CEP))
    医歯薬出版 2009年
  19. 19. 医学のあゆみ 松阪,諭 (担当:分担執筆, 範囲:抗体医薬に対するバイオマーカー-末梢循環癌細胞(CTC), 末梢循環血管内皮細胞(CEC), 末梢循環血管内皮前駆細胞(CEP))
    医歯薬出版 2009年
  20. 20. Gan To Kagaku Ryoho 松阪,諭 (担当:分担執筆, 範囲:Biomarker for chemotherapy in patients with colorectal cancer)
    2009年
  1. 1. Label-free three dimensional optical coherence tomography (OCT-) based imaging method for drug response evaluation of human derived tumor spheroids Abd El-Sadek; Ibrahim; Miyazawa, Arata; Mori, Tomoko; Shen, Larina Tzu-Wei; Makita, Shuichi; Mukherjee, Pradipta; Matsusaka, Satoshi; Yasuno, Yoshiaki
    Photonics West 2022年2月22日
  2. 2. Three dimensional tumor spheroid drug response evaluation using OCT based tissue viability evaluation method Abd El-Sadek; Ibrahim; Miyazawa, Arata; Mori, Tomoko; Shen, Larina Tzu-Wei; Makita, Shuichi; Mukherjee, Pradipta; Matsusaka, Satoshi; Yasuno, Yoshiaki
    Photonics West 2022年2月22日
  3. 3. Label-free three dimensional evaluation of tumor spheroid drug response using dynamics optical coherence tomography Abd El-Sadek; Ibrahim; Miyazawa, Arata; Shen, Larina Tzu-Wei; Mori, Tomoko; Makita, Shuichi; Mukherjee, Pradipta; Matsusaka, Satoshi; Yasuno, Yoshiaki
    Optics and Photonics Japan 2021年
  4. 4. がん分子標的治療の基本講座 セッション１９「CTC」 松阪, 諭
    第22回日本がん分子標的治療学会学術集会 基調講演
  5. 5. Symposium 6: Biomarker CTC, and circulating DNA 松阪, 諭
    Anti-Cancer Treatment
  6. 6. 「がん診断・治療におけるCTCの有用性と今後の展望」 松阪,諭
    化学とマイクロ・ナノシステム学会 第37回研究会 招待講演
  7. 7. ゲノム解析を目指したCTC診断装置の開発 松阪, 諭
    第4回Liquid Biopsy研究会 シンポジウム「ゲノム医療の時代におけるリキッドバイオプシーの役割」

 832 total views